Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4638473 | 0.92 | ALDH1A1 (0.65) | ALDH1A1GAACYP19A1TSHRPOLB | |
| SCHEMBL4706773 | 0.89 | ALDH1A1 (0.49) | ALDH1A1GAACYP19A1TSHRPOLB | |
| SCHEMBL4707976 | 0.86 | CYP19A1 (0.57) | ALDH1A1GAACYP19A1TSHRPOLB | |
| SCHEMBL4708362 | 0.85 | ALDH1A1 (0.56) | ALDH1A1GAACYP19A1TSHRADORA3 | |
| SCHEMBL4707735 | 0.85 | TACR1 (0.52) | ALDH1A1GAACYP19A1TSHRPTGER4 | |
| SCHEMBL4637752 | 0.85 | CYP19A1 (0.74) | ALDH1A1GAACYP19A1TSHRPOLB | |
| SCHEMBL4637826 | 0.84 | ALDH1A1 (0.47) | ALDH1A1GAACYP19A1TSHRPOLB | |
| SCHEMBL4638842 | 0.83 | CYP19A1 (0.48) | ALDH1A1GAACYP19A1TSHRPOLB | |
| SCHEMBL4638563 | 0.83 | ALDH1A1 (0.47) | ALDH1A1GAACYP19A1TSHRPOLB | |
| SCHEMBL6072058 | 0.82 | ALDH1A1 (0.53) | ALDH1A1GAACYP19A1TSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501809-B1 | TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20060160794-A1 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY | 2006-07-20 | — | — | US | disclosed |
| EP-1638944-A1 | TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005000821-A1 | TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160794-A1 | Tachykinin receptor antagonists | TACR1, TACR2, PROKR1 | ALDH1A1 1815/4885GAA 1942/4885CYP19A1 2652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.